In R/R Classical Hodgkin’s lymphoma AFM13 has been shown to demonstrate modest activity (ORR 23%), but when combined with PD1 inhibition, response rates were much improved (ORR 83%) [99], perhaps beyond what is expected of PD1 inhibition alone and suggestive of synergism; however, to date, no trials have been reported in CD30+ T-cell lymphoma. The gene discussed is TNFRSF8; the disease is T-cell non-Hodgkin lymphoma.